Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium
ECONOMY & POLICY

Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.

Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as "the future of cancer treatment". Rosatom and healthcare facilities are actively working in this field.

"Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science," said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.

The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation. Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as the future of cancer treatment. Rosatom and healthcare facilities are actively working in this field. Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science, said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC. The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Next Story
Resources

Haworth India Hosts Women’s Leadership Panel Series

Haworth India marked International Women’s Day by hosting a leadership roundtable series titled ‘Give to Gain’, bringing together senior women leaders from architecture and design firms, corporates and project management consultancies. The series has been conducted in Delhi and Mumbai, with upcoming sessions scheduled in Bengaluru and Hyderabad on 27 March 2026. Structured as moderated panel discussions followed by audience interaction, the initiative examined the business impact of women’s leadership and the role of inclusive workplaces in supporting professional growth. Manish Khan..

Next Story
Real Estate

Max Estates Secures RERA For Max One Project

Max Estates has secured RERA approval (UPRERA No.: UPRERAPRJ9759) for its Max One development around Max Towers in Sector 16B, Noida, bringing renewed progress to a project previously stalled following the insolvency of its earlier developer. Spread across around 10 acres with an estimated development potential of about 2.5 million sq ft, Max One is planned as an integrated mixed-use campus combining serviced residences, premium offices, retail spaces and a private club. The project is expected to generate total sales potential of about Rs 20 billion along with an estimated annuity rental inc..

Next Story
Real Estate

Hindware Introduces Starc Smart Wall Mount Toilet

Hindware has introduced the Starc Smart Wall-Mount Toilet under its Hindware Italian Collection, designed to combine automation, hygiene and contemporary bathroom aesthetics. The model features automatic flushing, sensor-based seat opening and closing, and remote-controlled functions. It also includes an oscillating water spray and warm air dryer for cleaning, along with a self-cleaning nozzle designed to maintain hygiene. Additional features include adjustable heated seating, customisable water temperature and pressure settings, a foot-touch flush system and an LCD control interface. The wa..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement